Bifeprunox
- Generic Name
- Bifeprunox
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N3O2
- CAS Number
- 350992-10-8
- Unique Ingredient Identifier
- AP69E83Z79
- Background
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
- Indication
Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.
- Associated Conditions
- -
- Associated Therapies
- -
Bifeprunox in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00193713
Bifeprunox in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 986
- Registration Number
- NCT00193687
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00160147
- Locations
- ๐บ๐ธ
Site 910, Santa Ana, California, United States
๐บ๐ธSite 902, Carson, California, United States
๐บ๐ธSite 911, Pasadena, California, United States
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00141479
- Locations
- ๐บ๐ธ
Site 1, Wichita, Kansas, United States
PK Effects of Bifeprunox & Valproate in Bipolar I
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00141505
- Locations
- ๐บ๐ธ
Site 1, Atlanta, Georgia, United States
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00139919
- Locations
- ๐บ๐ธ
Site 1, Orange, California, United States
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00139906
- Locations
- ๐บ๐ธ
Site 1, National City, California, United States
Study Evaluating Bifeprunox in Bipolar Depression
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 434
- Registration Number
- NCT00134459
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath